Hormonal Therapy in Nonmetastatic Breast Cancer

  • Radhakrishna Selvi


Breast cancer is one of the few cancers which are under hormonal regulation, and the manipulation of hormonal control has shown marvelous results. Role of hormones in breast cancer was first highlighted when it was observed that in certain patients, the diseased regressed with the onset of menopause. This was further consolidated when similar regression was observed by Beaston, that in many premenopausal women the disease regresses after surgical oophorectomy. Hormone-positive breast cancers account for nearly two third of total breast cancer patients. Hormonal therapy has proven its effectiveness in both adjuvant and advanced settings and also known to be devoid of major toxicities.


Breast Cancer Endometrial Cancer Premenopausal Woman National Comprehensive Cancer Network National Comprehensive Cancer Network 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Jensen EV. On the mechanism of estrogen action. Perspect Biol Med. 1962;6:47–59.PubMedGoogle Scholar
  2. 2.
    Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet. 1998;351(9114):1451–67.Google Scholar
  3. 3.
    Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst. 2001;93(9):684–90.PubMedCrossRefGoogle Scholar
  4. 4.
    Cuzick J, Sestak I, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010;11(12):1135–41.PubMedCrossRefGoogle Scholar
  5. 5.
    Senkus E, Kyriakides S, Penault-Llorca F, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 Suppl 6:vi7–23.PubMedCrossRefGoogle Scholar
  6. 6.
    Early Breast Cancer Trialists’ Collaborative Group, Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771–84.PubMedCrossRefGoogle Scholar
  7. 7.
    Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010;28(3):509–18.PubMedCrossRefGoogle Scholar
  8. 8.
    Thomas R. Examining quality of life issues in relation to endocrine therapy for breast cancer. Am J Clin Oncol. 2003;26(4):S40–4.PubMedCrossRefGoogle Scholar
  9. 9.
    Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res. 2007;9(1):R6.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2010;28(30):4594–600.PubMedCrossRefGoogle Scholar
  12. 12.
    Ovarian ablation in early breast cancer: overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet. 1996;348(9036):1189–96.Google Scholar
  13. 13.
    Sawka CA, Pritchard KI, Shelley W, et al. A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: a report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA.1. Breast Cancer Res Treat. 1997;44(3):211–5.PubMedCrossRefGoogle Scholar
  14. 14.
    NCCN clinical practice guidelines in oncology (NCCN guidelines), breast cancer (version 1.2014). http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
  15. 15.
    Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–717.CrossRefGoogle Scholar
  16. 16.
    Regan MM, Neven P, Giobbie-Hurder A, et al. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncol. 2011;12(12):1101–8.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Colleoni M, Giobbie-Hurder A, Regan MM, et al. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol. 2011;29(9):1117–24.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Bliss JM, Kilburn LS, Coleman RE, et al. Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study. J Clin Oncol. 2012;30(7):709–17.PubMedCrossRefGoogle Scholar
  19. 19.
    Dubsky PC, Jakesz R, Mlineritsch B, et al. Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol. 2012;30(7):722–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Jin H, Tu D, Zhao N, Shepherd LE, Goss PE. Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover. J Clin Oncol. 2012;30(7):718–21.PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Goss PE, Ingle JN, Pater JL, et al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol. 2008;26(12):1948–55.PubMedCrossRefGoogle Scholar
  22. 22.
    Mamounas EP, Jeong JH, Wickerham DL, et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial. J Clin Oncol. 2008;26(12):1965–71.PubMedCrossRefGoogle Scholar
  23. 23.
    Burstein HJ, Griggs JJ, Prestrud AA, Temin S. American society of clinical oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Oncol Pract. 2010;6(5):243–6.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    van de Velde CJ, Rea D, Seynaeve C, et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet. 2011;377(9762):321–31.PubMedCrossRefGoogle Scholar
  25. 25.
    Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805–16.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Gray RG, Rea D, Handley K, et al. aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol. 2013;31sl: abstr 5.Google Scholar
  27. 27.
    Group LH-aiEBCO, Cuzick J, Ambroisine L, et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet. 2007;369(9574):1711–23.PubMedCrossRefGoogle Scholar
  28. 28.
    Baum M, Hackshaw A, Houghton J, et al. Adjuvant goserelin in pre-menopausal patients with early breast cancer: results from the ZIPP study. Eur J Cancer. 2006;42(7):895–904.PubMedCrossRefGoogle Scholar
  29. 29.
    Charehbili A, Fontein DB, Kroep JR, et al. Neoadjuvant hormonal therapy for endocrine sensitive breast cancer: a systematic review. Cancer Treat Rev. 2014;40(1):86–92.PubMedCrossRefGoogle Scholar

Copyright information

© Springer India 2015

Authors and Affiliations

  • Radhakrishna Selvi
    • 1
  1. 1.Chennai Breast CentreChennaiIndia

Personalised recommendations